Drug intelligence / Profile preview

NSV0001

Development stage: Phase 1
Lead developer: Nitto
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Sublingual

Overview

NSV0001 is a quadrivalent influenza vaccine candidate developed for sublingual administration. It utilizes a novel adjuvant (ND002) and is designed to induce immunity against four strains of influenza virus. The vaccine is based on recombinant protein technology targeting the hemagglutinin (HA) antigen, aiming to provide broad protection against seasonal influenza. The primary developer of this vaccine is Nitto Denko Corporation. Clinical trials have evaluated its safety and immunogenicity in healthy adults[2][7].

Targets

HA0 (Influenza B virus hemagglutinin)

Beyond the preview

Go deeper on NSV0001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NSV0001.

Explore the full profile